The primary focus of the Cell Death Regulation Group at IDIBELL is to understand how cells die when they lack essential nutrients and how they communicate with the tissue. Their aim is to use this knowledge to develop better therapies for cancer treatment or against ischemic diseases such as stroke. They are an international group with numerous local and international collaborations in the fields of cell death, the immune response and cancer metabolism.
Bellvitge Biomedical Research Institute (IDIBELL)
Hospital Duran i Reynals, 3a planta
Gran Via de l’Hospitalet, 199
08908 L’Hospitalet del Llobregat